← Back to patent-cliff list
SBK-001
Tier C — Watch / tradeSBK-001
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：MUC5AC
Indications (approved)：Lung disease, Chronic bronchitis, Postoperative complication, Asthma, Bronchitis, Cough, Acute lung injury
Regional status
US
-
EU
-
China
Phase III
2026-09-22
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of SBK-001?
Approved indications include: Lung disease, Chronic bronchitis, Postoperative complication, Asthma, Bronchitis, Cough, Acute lung injury.
When does the SBK-001 patent expire?
No public expiry year is available for SBK-001 yet; this page updates once verified.
How do I get a quote for SBK-001 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-28